Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
about
Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis.A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients.Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disordersModulation ofTcf7l2 expression alters behavior in mice.An in vivo cis-regulatory screen at the type 2 diabetes associated TCF7L2 locus identifies multiple tissue-specific enhancers.Efficacy of lifestyle interventions in physical health management of patients with severe mental illness.The genetic validation of heterogeneity in schizophrenia.Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study).Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.Glucose abnormalities in the siblings of people with schizophrenia.Increased Expression of the Diabetes Gene SOX4 Reduces Insulin Secretion by Impaired Fusion Pore ExpansionParental history of type 2 diabetes in patients with nonaffective psychosis.Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms.Does Schizophrenia in Offspring Increase the Risk of Developing Alzheimer's Dementia.A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysisSchizophrenia genetics: new insights from new approaches.Development of diabetes mellitus associated with quetiapine: A case series.Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review.Lipid effects of psychiatric medications.Diabetes mellitus and severe mental illness: mechanisms and clinical implications.Serious mental illness and medical comorbidities: Findings from an integrated health care system.Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia.Reducing cardiovascular risk factors in non-selected outpatients with schizophrenia.Growth pattern and risk of schizophrenia.Common familial risk factors for schizophrenia and diabetes mellitus.Human Rho Guanine Nucleotide Exchange Factor 11 (ARHGEF11) Regulates Dendritic Morphogenesis.Clustering of schizophrenia with other comorbidities--what can we learn?Converging evidence that sequence variations in the novel candidate gene MAP2K7 (MKK7) are functionally associated with schizophrenia.Improving quality of life and physical health in patients with schizophrenia: A 30-month program carried out in a real-life setting.Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in Singapore.Human Rho guanine nucleotide exchange factor 11 gene is associated with schizophrenia in a Japanese population.Olanzapine: review of safety 2008
P2860
Q30458875-CCE43921-066B-4377-BB6C-086372936A14Q33288884-4FC5F121-0FDE-4760-94F6-B6D36D367C44Q33703032-9FEFA30C-23E2-4C90-8759-67F36363DA29Q34064796-22A908BB-136A-480F-80A2-B17725F999B4Q34270782-19B39D87-F8F4-43E1-8A8C-3245739DEEC5Q35290463-A489076E-81B4-4946-ABE4-CBD00470BE35Q35415495-B118D777-1081-4972-ABF9-96610CA40791Q35460642-49323ED2-39D3-4611-9B48-22102BF7A762Q36893286-0D6BABCE-5591-4AA7-916F-24E869478A46Q37151239-3A5AFD80-F344-4F83-9E7B-3BF551D3E46FQ37200679-507B195A-E7B0-4296-9E62-7C9D833EE3C9Q37245448-EC90B1A9-5CDC-4997-B744-BB5A205AD1F6Q37247852-CDFD83D6-D585-4626-9CCF-8B6A62715494Q37293621-A525B472-9A99-4872-BFA5-BAC18342406FQ37435547-5D02ACF0-70F4-4AAE-A196-1282B547B0B9Q37483078-E41A3146-6DA5-4DBB-81D3-3E41D322228AQ37613388-8AD042A4-9B70-40FC-B788-D1FE0B98B38DQ37865505-3E073A71-3D8A-43AD-A7F4-94A25441C4B7Q37896627-48424109-94C6-4FF9-8A89-A0CD2356B545Q37996445-D69208D3-5091-47A6-BF12-38F43B91C463Q38066118-BADA0DEB-49B3-4280-83E6-CA5338285799Q38274901-2D1BD0BF-8D73-4DFE-B1E6-5CFB17D11141Q38633456-C314FFB4-DB1A-4F44-AD1B-B08C1033F231Q38853963-98968C62-C8BE-4243-AB91-BAEBD0546FD0Q38890884-1E1D26C6-6360-4A77-9877-1AD2DB8418AEQ40212441-E2FF2962-E474-4531-80F2-1CAA705F8487Q40698256-42BB39F9-5BB0-48C5-B0BD-1F283DB603DCQ42323220-B3D0BF8F-5F31-4501-9B3B-D647A50A32B2Q43158437-796A2145-BEE3-4A97-970B-32AD59D15C43Q47253637-1906DF25-9C10-4579-9FFF-60F81981601EQ47759983-8CAEC12C-D56B-4123-8277-47FE06406E65Q50751012-DD73815F-CA28-4E1B-AC44-5C19147C5AD3Q55058612-611FF079-2CAE-4620-A37D-C39AC3E81B05Q56791028-E1C37A88-29C8-4403-A8B4-276E01305117
P2860
Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
@ast
Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
@en
type
label
Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
@ast
Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
@en
prefLabel
Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
@ast
Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
@en
P2860
P356
P1476
Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
@en
P2093
Stephen C L Gough
P2860
P356
10.1177/0269881105058380
P407
P433
P577
2005-11-01T00:00:00Z